

Amendment no. 3

NO. BPPI/DRUG/RC-128/2020

Dated: 04/03/2020

Subject: - Tender No. BPPI/DRUG/RC-128/2020 dated 11/02/2020 for supply of Drugs to Bureau of Pharma Public Sector Undertakings of India (BPPI).

Reference: - Pre-Bid meeting held on 18.02.2020 at 11:00 AM in the premises of BPPI

The following amendment in Tender Document is hereby authorized:

PART- A

Sl. No.	Tender Clause/Reference	Query/Suggestion	Clarification/ Amendment
1	Page 2 of the tender document and Annexure -XII Clause 18 E & (F)	One of the representatives of the bidder has requested the following points in the Pre-bid meeting: - a. Requested to extend the last date of submission of the bid. b. Representative of another firm has requested to extend the tender for next two months informing about the extension given in other state government tenders. c. The bidder has also requested to reduce the tender validity from two year to six months or lower. d. They have requested to reduce the tentative required quantity of the drugs to limited projected quantity.	Last date of submission of tender is already amended. For remaining points b, c and d tender condition prevails
2	Clause no. 19. SUPPLY CONDITIONS (d)	One of the prospective bidders requested to increase the delivery schedule from 45 days to 60 days where the “Delivery Schedule against first P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)” .	Tender condition prevails.
3.	Annexure -XIII clause 19(K)	A bidder has requested seeking amendment in shelf life of vitamin products saying vitamin are not stable more than 18 and multivitamin products are not stable more than 12 to 18 months.	In any case the shelf life shall not be less than 18 months.

4.	Clause No. 3 (i)	One of the prospective bidders has requested to relax turnover	Tender condition prevails.
----	------------------	--	----------------------------

PART B: - (i)

Sl. No.	Tender Clause/ Reference No.	Drug Code & Drug Specification	Query/Suggestion	Clarification/ Amendment
1	Annexure -VII Clause 8.1 & 8.2	Rabies Vaccine, Human IP Purified lyophilized Rabies antigen derived from Rabies virus (L. Pasteur 2061/ Vero strain propagated in Vero cells), Inactivated. Potency: ≥ 2.5 IU per Vial Stabilizers: Maltose and Human Albumin q. s.	Bidder has requested to amend the specification of DC 574 Rabies Vaccine, Human IP	The following amendment in unit size for Drug Code 574 Anti-Rabies Vaccine (Purified Chick embryo cell) 2.5 IU, 1ml vial Unit Size: 1ml with Diluent
2	Sl. No. 105, 106 and 107 of Annexure -XII, Annexure -XIII and Annexure -XIV	Drug code 1461 (Vildagliptin 50mg Uncoated Tablet), Drug code 1462 (Vildagliptin 50mg and Metformin HCl IP 500mg film coated film coated Tablet), Drug code 1463 (Vildagliptin 50mg and Metformin HCl IP 1000mg Tablet),	For Drug code 1461 (Vildagliptin 50mg Uncoated Tablet), Drug code 1462 (Vildagliptin 50mg and Metformin HCl IP 500mg film coated film coated Tablet), and Drug code 1463 (Vildagliptin 50mg and Metformin HCl IP 1000mg Tablet), one of the prospective bidder has requested to relax market standing certificate informing that patent for these drugs has recently expired.	Market Standing Certificate for mentioned drug code 1461 (Vildagliptin 50mg Uncoated Tablet), Drug code 1462 (Vildagliptin 50mg and Metformin HCl IP 500mg film coated film coated Tablet), and Drug code 1463 (Vildagliptin 50mg and Metformin HCl IP 1000mg Tablet) is hereby relaxed.
3	Annexure XIV for DC 143	Drug code 143 (INSULIN INJECTION (INSULIN HUMAN SOLUBLE 30% & ISOPHANE 70%) 40 IU/ML)	One of the bidders requested to amend the mismatch in shape, colour, packing type etc. of drugs in Annexure XIV for DC 143	The following amendment is hereby authorized- Shape and Size: Glass Vial
4	Annexure -XII Clause 18 E & (F)	Drug code 817 (Calcium Carbonate 1250 Mg Vitamin D3 250 Iu Magnesium Oxide 40 Mg Manganese Sulphate 1.8 Mg Zinc)	It was observed that dosage form of the product is missing in the specification	The following amendment is hereby authorized in the specification: - Drug code 817 (Calcium Carbonate 1250 Mg Vitamin D3 250 IU Magnesium Oxide 40 Mg

				Manganese Sulphate 1.8 Mg Zinc Tablet.
5	Annexure XIV	DC- 287 Losartan 50 mg and HydroChorthaizide 12.5 mg Tablet DC- 288 Losartan film coated Tablets IP 25mg DC- 290 Metoprolol 25 mg I.P Tablet DC- 293 Ramipril Tablets IP 2.5mg DC- 294 Ramipril Tablets IP 5mg DC- 422 TORASEMIDE Tablets IP 10mg DC- 456 ATORVASTATIN Tablets IP 40 mg DC- 512 Aceclofenac 100 mg + Paracetamol 325 mg + Serratiopeptidase 15 mg Tablets	One of the Bidder has offered and requested to change the packing type as mentioned in the tender like Blister packing, strip packing etc.	Tender condition prevails

(ii) The following drug is hereby stands deleted from BOQ (Cover B), Annexure XII, Annexure XIII and Annexure XIV.

S.N.	Drug Code	Generic Name of Drug	Unit Size	Pack Size
1	364	GLIMEPIRIDE 2 mg + METFORMIN HYDROCHLORIDE 500 mg SR Tablets 10's	10's	10's X 10
2	1239	GLIMEPIRIDE 2 mg + METFORMIN HYDROCHLORIDE 500 mg SR Tablets,15's	15's	15's X 10

The bidders are requested to quote their rate in BOQ considering above amendment/modification/Deletion of drugs in tender document and specification, unit size, pack size in Annexure VII Annexure VIII and BOQ and Amendment in Annexure XII, Annexure XIII and Annexure XIV.

All other contents of tender document remain unaltered.

Sd/-
(Anurag Dwivedi)
GM (Procurement & Q.C.)
For & on behalf of BPPI